Today: 20 May 2026
Bitmine Immersion (BMNR) stock in focus after $13.2B crypto stash update as year-end trading thins
30 December 2025
2 mins read

Bitmine Immersion (BMNR) stock in focus after $13.2B crypto stash update as year-end trading thins

NEW YORK, December 30, 2025, 03:48 ET — Market closed

Shares of Bitmine Immersion Technologies last traded at $28.54, up 0.8% from the previous close, after swinging between $27.80 and $29.60 in Monday’s session. The company said its crypto, cash and other investments totaled $13.2 billion as of Dec. 28, including 4,110,525 ether — the token of the Ethereum blockchain — at $2,948 each, 192 bitcoin, $1.0 billion in cash, a $23 million stake in Eightco Holdings and 408,627 staked ether. “Year-end tax-loss related selling is pushing down crypto and crypto equity prices,” Chairman Thomas “Tom” Lee said, noting Bitmine added 44,463 ether in the past week. SEC

Bitmine sits in a growing corner of the market where listed companies use equity capital to build large cryptocurrency “treasuries,” turning their stocks into proxies for the underlying tokens. That structure can amplify moves in both directions when investors rotate toward or away from risk.

The timing matters heading into year-end, when liquidity often thins and crypto prices can move sharply. Bitcoin was down about 2% and ether was off about 1.3% early Tuesday, pressuring the broader group of crypto-linked equities.

A filing on Monday showed Bitmine also distributed a shareholder presentation, a video and an audio message tied to its upcoming annual meeting. The materials were furnished under a Form 8-K filing, the document U.S. companies use to disclose major events between regular reports.

In its proxy statement, Bitmine told shareholders the annual meeting will be held on Jan. 15 in Las Vegas. The agenda includes director elections and a proposal to increase the number of authorized shares — the ceiling on shares a company can issue — alongside votes on an incentive plan and a performance-based compensation arrangement for the executive chairman.

Authorized-share proposals tend to land hard in crypto-treasury trades because many of them fund token purchases through stock issuance. Strategy, the largest corporate bitcoin holder, has leaned on share sales to finance buys — a model that has drawn investor scrutiny during bitcoin pullbacks.

With most of Bitmine’s balance sheet tied to ether and other crypto assets, investors will keep comparing the share price to the company’s net asset value per share — essentially what its tokens and cash are worth after dividing by shares outstanding. When the stock trades well above that value, issuing shares to buy more tokens can be accretive; when it trades below, dilution fears usually rise.

Staking is another lever investors watch because it aims to turn idle tokens into yield. It involves locking up tokens to help run a blockchain network in exchange for rewards, similar to earning interest, though returns can vary with network conditions and fees.

Bitmine has been a volatile name since mid-2025, when it drew broader market attention as more public firms started building crypto-heavy treasuries. Reuters reported in July that billionaire Peter Thiel disclosed a 9.1% stake in the company, a filing that sent the shares sharply higher at the time.

Before the next session, investors will be watching the release of minutes from the Federal Reserve’s latest policy meeting for clues on how long rates may stay restrictive. Rate expectations often influence crypto and other risk assets by shifting the appeal of cash and government bonds.

Trading conditions could also stay choppy into the end of the year, with U.S. stock markets open on New Year’s Eve but closed on New Year’s Day, while the bond market closes early on Dec. 31. Thin trading can exaggerate moves in smaller, high-beta stocks such as BMNR.

Stock Market Today

  • Sea Limited (NYSE:SE) Valuation Under Scrutiny After 46% One-Year Share Decline
    May 20, 2026, 10:05 AM EDT. Sea Limited (NYSE:SE), active across e-commerce, digital financial services, and digital entertainment in Southeast Asia and Latin America, has seen its stock fall by 46.26% over the past year. Despite recent share price weakness, some analysts argue the stock trades 36.6% below a $137.64 fair value estimate, buoyed by strong revenue growth from Shopee, Monee, and Garena platforms. Key drivers include accelerating mobile internet penetration, youth digital literacy, and shifts toward cashless payments supporting loan book expansion and improved monetization. Market watchers debate whether this dip offers a buying opportunity or reflects tempered growth prospects, especially as Shopee faces competitive pressures. Investors should weigh Sea's potential for earnings growth against market realities and execution risks.

Latest articles

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

20 May 2026
Vida Global Inc. raised $15 million in its May 18 IPO, selling 3.75 million shares at $4 each, but the stock closed at $2.29 on Tuesday. CEO Lyle Pratt bought 312,900 shares for about $1.19 million, according to a Form 4 filing. Vida reported 2025 revenue of $551,383 and a net loss of $2.9 million. The company’s shares trade on NYSE American and NYSE Texas under the symbol VIDA.
TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

20 May 2026
TJX raised its fiscal 2027 sales, earnings, and buyback targets after first-quarter comparable sales rose 6% and net income hit $1.3 billion. Shares climbed 3.6% in premarket trading. The company cited higher fuel costs as a drag on its full-year forecast. Marmaxx, HomeGoods, and TJX Canada all posted strong sales growth.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

20 May 2026
The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
Bitcoin ATM scam costs Nebraska couple $250,000 as crypto kiosk fraud draws fresh warnings
Previous Story

Bitcoin ATM scam costs Nebraska couple $250,000 as crypto kiosk fraud draws fresh warnings

NIO stock today: Premarket ticks higher as CATL battery shift report meets 2026 demand warning
Next Story

NIO stock today: Premarket ticks higher as CATL battery shift report meets 2026 demand warning

Go toTop